Genome editing of human induced pluripotent stem cells (hipscs) offers unprecedented opportunities for in vitro disease modeling and personalized cell replacement therapy. the introduction of cas9-directed genome editing has expanded adoption of this approach. However, marker-free genome editing using standard protocols remains inefficient, yielding desired targeted alleles at a rate of ~1-5%. We developed a protocol based on a doxycycline-inducible Cas9 transgene carried on a piggyBac transposon to enable robust and highly efficient cas9-directed genome editing, so that a parental line can be expeditiously engineered to harbor many separate mutations. treatment with doxycycline and transfection with guide rna (grna), donor Dna and piggyBac transposase resulted in efficient, targeted genome editing and concurrent scarless transgene excision. using this approach, in 7 weeks it is possible to efficiently obtain genome-edited clones with minimal off-target mutagenesis and with indel mutation frequencies of 40-50% and homology-directed repair (HDr) frequencies of 10-20%.
IntroDuctIon
hiPSCs offer an unprecedented opportunity for in vitro disease modeling and for personalized cell replacement therapy 1 . Applications of iPSCs have been greatly expanded by the advent of genome editing, in which the genomic sequence at a target site is altered by insertion or deletion ('indel') mutations, or by introduction of precisely programmed ('knockin') modifications 2 . Here we present a highly efficient and reproducible protocol to edit the genome of hiPSCs through the combined use of the CRISPR/Cas9 RNA-guided nuclease and piggyBac transposase [3] [4] [5] . This protocol is best suited to applications in which a common starting cell line is edited many different times to yield isogenic daughter cell lines that differ by the introduced mutations.
Genome editing relies on the introduction of a double-strand break at a target locus using 'designer nucleases' that selectively target one site in the genome. The cell repairs the double-strand break through either nonhomologous end joining (NHEJ), creating indel mutations, or HDR, resulting in knock-in modification near the nuclease cutting site. Potential nuclease platforms include zinc-finger nucleases and transcription-activator-like effector nucleases 6 . However, designing these nucleases is labor-intensive and not readily multiplexed. More recently, the CRISPR/Cas9 nuclease has emerged as a powerful and malleable tool to introduce targeted double-strand breaks 6 . Unlike zinc-finger nucleases and transcription-activator-like effector nucleases, Cas9 specificity is determined by Watson-Crick base pairing between an engineered gRNA and the target site 7, 8 . As a result, Cas9 targeting is easily achieved by synthesizing the desired gRNA.
Although Cas9 efficiently directs target-site cleavage, the efficiency of targeted genome modification was initially reported to be ~1-2% in hiPSCs 7, 9 . At this efficiency, recovery of properly targeted clones without positive selection is labor-intensive and inconsistent. We and others previously showed that low transfection efficiency of the relatively large Cas9 expression construct limits the yield of targeted clones in pluripotent stem cells 10 . Procedures that select for Cas9-transfected cells, such as cell sorting for a fluorescent protein expressed from a co-transfected plasmid, increase the recovery of modified clones 11 . However, cell sorting is stressful for stem cells, exposes them to contamination risks and can be cumbersome when performing modifications on multiple cell lines in parallel. Gonzalez et al. 12 showed that knock-in of inducible Cas9 into a safe harbor locus enhances the genome-editing efficiency. However, this strategy consumed the adeno-associated virus integration site 1 (AAVS1) safe harbor locus, and the Cas9 transgene was not excisable. We have refined this strategy and present here an optimized protocol to permit footprint-free, highly efficient and consistent genome modification in hiPSCs. This procedure can be used to develop isogenic cell lines that differ from each other by sequence variations introduced by genome editing, as we described for an iPSC-based model of Barth syndrome (BTHS) 3 . The high efficiency of the procedure can also be used to simultaneously disrupt multiple genes or sequences that are present multiple times in the genome. For example, we used this strategy to simultaneously disrupt 62 copies of porcine endogenous retrovirus in a porcine cell line 5 . The inducibility of Cas9 in our system might also be exploited to permit temporally controlled gene inactivation in cells differentiated from iPSCs, thereby potentially circumventing the need to establish stable mutant cell lines.
Development of the protocol: Dox-inducible Cas9 transgene encapsulated on a piggyBac transposon
We reasoned that Cas9 genome-editing efficiency could be enhanced by generating a stable cell line that harbors an inducible Cas9 transgene encapsulated on a piggyBac transposon (Fig. 1a) . Genome editing is performed by Cas9 induction accompanied by transfection of gRNA and a HDR DNA donor template. The Cas9 transgene can be removed by transient transfection with piggyBac transposase.
We generated a doxycycline-inducible, human-codon-optimized Cas9 (hCas9) construct contained within a piggyBac transposon 7 . The piggyBac transposon construct was stably introduced into the male PGP1-iPS cell line by co-transfecting it with a plasmid encoding the piggyBac transposase (Fig. 1b,c) . The resulting PGP1-hCas9-PB stable cell line showed >1,000-fold induction of Cas9 by doxycycline (Dox) treatment (Fig. 1d) .
Stable expression of hCas9 allowed us to efficiently target a human disease gene in iPSCs. We targeted Tafazzin (TAZ), a gene on the X chromosome that is mutated in BTHS, a mitochondrial cardiomyopathy 13 . We designed a gRNA and an HDR template to introduce a known BTHS mutation (c.517delG) 14 into TAZ exon 6 and co-transfected them into PGP1-hCas9-PB with Dox treatment. The surveyor mutation detection assay suggested efficient TAZ gene modification with Dox treatment, and no detectable modification in the absence of Dox (Fig. 2a) . High-throughput sequencing of the targeted locus from pooled genomic DNA 9 showed that 30% of cells had an indel near the engineered doublestrand break, whereas 50% had undergone HDR and harbored the sequence variant programmed by the HDR donor (Fig. 2b) .
We evaluated the recovery of individual TAZ-modified clones. After transfection with gRNA and the HDR donor, cells were plated at low density and treated with Dox. Colonies were then picked and genotyped by DNA sequencing. Of 42 clones sequenced, 13 (31%) contained an indel and 16 (38%) contained the donorprogrammed sequence variant (Fig. 2c,d ). The efficiency of our strategy and protocol has been further tested in a different human embryonic stem cell line and at different loci, with HDR rates of ~20-35% and NHEJ rates of ~50% (Supplementary Fig. 1 ).
Development of the protocol: excision of the Dox-inducible
Cas9 transgene by piggyBac transposase Encapsulating the hCas9 transgene on a piggyBac transposon enabled its efficient excision. To illustrate this, we transiently transfected PGP1-hCas9-PB-TAZ c.517delG with an excision-competent, integration-defective piggyBac tranposase expression plasmid 15 and assessed hCas9 transgene excision by loss of puromycin resistance, encoded on the piggyBac transposon. PiggyBac transposase reduced the frequency of puromycin-resistant clones, as assessed by crystal violet visualization of puromycin-resistant clones, demonstrating efficient transposon excision (Fig. 3a) . Most individual clones recovered after transient piggyBac transposase expression were negative for the hCas9 transgene, as determined by PCR genotyping. For establishment of the PGP1-TAZ c.517delG line lacking the hCas9 transgene, we genotyped 34 clones, and 22 (64%) had undergone successful transgene removal (Fig. 3b) . We have further streamlined the protocol by introducing piggyBac transposase into Dox-induced cells in the same transfection as gRNA and donor DNA. We found that co-transfection of the excision-only piggyBac mutant did not substantially reduce the yield of genome-edited clones, yet most of the recovered clones had still successfully Fig. 2 ). Thus, including the excision-only piggyBac mutant in the transfection mix with gRNA and donor DNA permits efficient, single-step genome editing and transgene excision.
Development of the protocol: quality control of recovered clones
We performed quality control on the genome-edited cell lines. PGP1e-TAZ c.517delG cells had a normal karyotype ( Supplementary  Fig. 3a) , expressed the pluripotency genes OCT4 and NANOG at levels comparable to the human embryonic stem (ES) cell line H7 ( Supplementary Fig. 3b,c) and differentiated into all three germ layers in teratoma assays ( Supplementary Fig. 3d-g ). The cell lines differentiated efficiently into cardiomyocytes using a common directed differentiation protocol ( Supplementary  Fig. 3h ) 16 . Indeed, we showed that the genome-edited PGP1e-TAZ c.517delG iPSC line effectively recapitulates hallmarks of BTHS ( Supplementary Fig. 4) . A concern of Cas9-based genome-editing strategies has been off-target mutagenesis. Recently, several studies used wholegenome sequencing to demonstrate that Cas9 genome editing does not substantially affect the mutation burden of iPSCs 4, 17, 18 . We confirmed that our strategy is not substantially mutagenic by deep sequencing of 31 potential off-target sites (Fig. 4a) . At each site, we sequenced a minimum of 100,000 amplicons, which we have previously shown to yield a detection sensitivity of 0.07% 4 . At the 31 computationally predicted potential off-target sites, 30 sites had three nucleotide mismatches to the reference genome. Significant off-target activity was not detected at these sites. The final site, site 28, was designed to also have three nucleotide mismatches to the reference sequence, but as we reported previously 4 , a single-nucleotide polymorphism (SNP) in the PGP1 genome sequence eliminated one mismatch. This site with two mismatches was frequently mutated, highlighting the potential for SNPs to affect off-target mutagenesis at specific sites. Whole-genome sequencing of six individual clones isolated using this protocol from separate genome-editing experiments at three loci (TAZ, DNAJC19 and JUP) showed that Cas9 does not induce frequent off-target mutagenesis. However, between 1 and 3 mutations that were probably linked to Cas9 were identified in each of the clones (Fig. 4b) . With only one exception, we did not detect significant off-target activity at sites with three or more gRNA mismatches. The exception (site B, Fig. 4b ) consisted of an indel mutation at a genomic site on chromosome 14 that matched the gRNA at bases [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (where position 1 is adjacent to the protospacer-adjacent motif (PAM)). However, 'seed' nucleotides 1-7 did not match, and the PAM sequence, GGT, has no predicted activity 19 . An identical computationally predicted potential off-target sites for TAZ gRNA. Cas9-PB iPSCs were treated with DOX+TAZ gRNA+donor. Off-target activity at 31 sites was analyzed by PCR amplification of the candidate sites from pooled genomic DNA, followed by deep sequencing (>100,000 sequences per site). The candidate sites had three mismatches from the gRNA, with the exception of site 28, which had a SNP that created a 2-bp mismatch, as we previously reported 4 . 'Cas9 no PB' and 'Cas9 with PB' refer to omission or inclusion of piggyBac transposase expression plasmid in the transfection of gRNA and DNA donor. 'TAZ HDR' and 'TAZ NHEJ' indicate the frequency of on-target HDR and NHEJ at the TAZ locus. (b) Whole-genome sequencing of six independently isolated clones derived from PGP1-Cas9-PB (listed under WGS sample) after targeting at three loci (TAZ, DNAJC19 and JUP). HDR or NHEJ indicates the type of mutation found at the target site. In each whole-genome sequence, we identified 10-15 indels. These were analyzed for homology to the gRNA, presence of protospacer-adjacent motif (PAM) sequences (blue) and recurrence in multiple clones or genomic locations. On the basis of this analysis, most of the indels were unrelated to the gRNA sequences and may have arisen spontaneously during clonal expansion from a single cell. Those that were related to the gRNA sequence are listed as 'offtarget indels' and named with a number if they were among the 31 predicted potential off-target sites (described in panel a; e.g., site 28) or a letter if they were not among these top 31 predicted off-target sites. Red letters indicate differences from the gRNA sequence, which is shown next to the locus name. The three separate TAZ clones sequenced all shared indels at the same two sites: site 28 and site A. Interestingly, site A differs from the gRNA target by only one nucleotide but was not computationally predicted because of its atypical PAM (CAG, pink underline). The two DNAJC19 clones had different indels at the same site, site B. An identical genomic sequence on a different chromosome (site C) also contained an indel in one of these clones. However, sites B and C had neither a functional PAM (orange underline) nor close homology to the gRNA within the Cas9 seed sequence. ^ indicates a site that is listed for completeness but may not have arisen from Cas9 activity (single occurrence; lack of PAM; multiple gRNA mismatches). Copynumber variation analysis of the whole-genome sequencing data found no significant copy-number variation in these clones. sequence exists on chromosome 3, and this site also contained an indel mutation in one of the two clones (site C, Fig. 4b ), suggesting that mutation at these sites was related to Cas9 activity. In addition, we detected clear off-target activity at a site (site A, Fig. 4b ) with a 1-bp gRNA mismatch but a variant PAM sequence, CAG, with known partial activity 19 . Together these results suggest that Cas9 does not induce widespread genomic instability or rearrangements but does induce off-target mutagenesis at rare sites that cannot be fully anticipated by current prediction rules.
We also investigated the potential for piggyBac excision to leave residual genomic scars. Our analysis (Supplementary Data 1) confirmed scarless piggyBac excision in all clones that we examined.
Limitations
Off-target mutagenesis is one potential consequence of genome editing. Whole-genome sequencing of several mutant iPSC lines generated through application of this protocol did not reveal a Box 1 | Design of gRNAs, HDR donor DNA oligonucleotide and genotyping primers.
Several excellent resources are available that provide detailed instructions on designing genome-editing reagents. Some of these are as follows: • Graham and Root, "Resources for the design of CRISPR gene editing experiments" 23 .
• The Addgene e-book, CRISPR 101: A Desktop Resource (http://www.addgene.org).
• Yang et al., "CRISPR/Cas9-directed genome editing of cultured cells" 24 .
grna expression construct
This procedure is described in greater detail in Yang et al. 24 . Although computational prediction of effective gRNAs has improved, there is still substantial variation in gRNA efficiencies. Therefore, it can be more efficient to generate several different gRNA constructs in parallel and then use them in Steps 28-47. Subsequent steps could then focus on the most efficient gRNA. 1. Find genomic sites of the form 5′-N19NGG-3′ (Fig. 5a ) within ± 50 bp of your intended target site (optimally within ±10 bp). The sequence can be on either strand. Publicly available gRNA design tools such as http://www.broadinstitute.org/rnai/public/ analysis-tools/sgrna-design are useful for selecting the most active gRNAs with the lowest chance of off-target activity. Additional design tools are described in Graham and Root 23 . For HDR, give priority to gRNAs located closest to the intended target site. 2. Replace the bold, red 'X' in the following sequence with the best N19 target sequence to yield the complete 455-bp sequence, which contains a U6 promoter and the gRNA. The U6 promoter prefers a G as the transcribed base, and we have incorporated this into the sequence as indicated by the green 'G': ATTCAGTCGA CTGGATCCGG TACCAAGGTC GGGCAGGAAG AGGGCCTATT  TCCCATGATT CCTTCATATT TGCATATACG ATACAAGGCT GTTAGAGAGA TAATTAGAAT TAATTTGACT GTAAACACAA  AGATATTAGT ACAAAATACG TGACGTAGAA AGTAATAATT TCTTGGGTAG TTTGCAGTTT TAAAATTATG TTTTAAAATG  GACTATCATA TGCTTACCGT AACTTGAAAG TATTTCGATT TCTTGGCTTT ATATATCTTG TGGAAAGGAC GAAACACCGX  GTTTTAGAGC TAGAAATAGC AAGTTAAAAT AAGGCTAGTC CGTTATCAAC TTGAAAAAGT GGCACCGAGT CGGTGCTTTT  TTTCTAGACC CAGCTTTCTT GTACAAAGTT HDr donor oligonucleotide 1. To generate donor DNA for oligo-mediated HDR, identify the positions targeted by the gRNA for cleavage and the desired modification site (Fig. 5b) . Include the 45 nt on either side of this modification region as the homology arms of the donor DNA. 45-nt homology arms are sufficient for base changes or small insertions (<40 nt). Larger insertions require larger homology arms 10 . If possible within the constraints of the desired experiment, introduce additional modifications in the HDR oligo that will alter the gRNA recognition sequence in the HDR donor oligo so that the oligo and the corrected genomic DNA will be refractory to gRNA-Cas9 cleavage. For instance, place silent mutations in the gRNA seed sequence, or disrupt the PAM sequence. It is also desirable to introduce or eliminate a restriction enzyme cleavage site to facilitate genotyping of candidate clones. 2. Synthesize the sequence as a single-stranded oligonucleotide at a 25-nmole scale. Desalted oligonucleotide is acceptable quality. Resuspend the oligonucleotide in ddH 2 0 at a stock concentration of 10 µg/µl.
Genotyping primers
1. Surveyor assay primers: forward and reverse primers should be designed to produce an amplicon of ~700 bp, positioned so that predicted cleavage products will be easily resolved (e.g., 200 and 500 bp) (Fig. 5b) . Each primer should be at least 70 bp from the target modification site. Resuspend at a 100 µM stock concentration and a 10 µM working concentration. PCR using the primers should yield a robust single band. 2. Sanger sequencing/PCR primers: forward and reverse PCR primers should be designed to be ~150 bp from the target modification site. These will be used to PCR-amplify the target region and to perform Sanger sequencing of the PCR amplicon. Resuspend at a 100 µM stock concentration and a 10 µM working concentration. substantial burden of off-target mutation, although each of the six cell lines that underwent whole-genome sequencing did acquire 10-15 off-target mutations each, of which 1-3 were attributable to gRNA-related Cas9 activity. Interestingly, the mutation sites were in some cases poorly predicted by current algorithms.
At present, whole-genome sequencing of each genome-edited clone is not feasible. Rather, we suggest that at least two independent clones be recovered for each genome-editing experiment. This will help to control for potential confounding effects of off-target mutations, although our whole-genome sequencing data show that some off-target sites are recurrently mutated in independent clones. Therefore, it is optimal to use two independent gRNAs. Rescue of mutant cells by transient cDNA expression is an alternative strategy to control for off-target mutation 3 .
This protocol requires establishing a parental cell line with the stably integrated transgene, which represents an extra step as compared with methods based on transient transfection coupled with cell-sorting-based enrichment of transfected cells. However, the benefit of our strategy is increased consistency and higher efficiency for recovering genome-edited clones once the parental line is established. Therefore, we use this strategy in situations in which it is desirable to make many different genome-edited cell lines from a common parent, such as when generating a series of cell lines that are isogenic, except for introduced mutations. On the other hand, this strategy would be cumbersome for editing many different cell lines, such as for correction of mutations in patient-derived iPSC lines.
Our method involves stable, random integration of Cas9, followed by scarless excision. It may be desirable in future iterations of this protocol to target a piggyBac-excisable Cas9 transgene to a safe harbor locus, such as AAVS1. This would eliminate problems with transgene copy number and reduce the chance of deleterious integration sites. Although our data suggest that piggyBac excision is robust and that the frequency of leaving a scar at the excision sites was below our detection limits (0/75 excision sites evaluated; Supplementary Data 1), a targeted integration strategy would nevertheless reduce the risk and facilitate validation of scar-free excision.
Experimental design gRNA and donor template design. Critical parameters that should be optimized for genome editing are the design of the gRNA and the HDR donor (Box 1). As we noted previously, SNPs not represented in the reference genome may lead to off-target sites not predicted by such design algorithms 4 . Genotyping strategy. It is critical to design the genome-editing strategy to facilitate genotyping of clones, as this step can otherwise be costly and rate-limiting. We have written this protocol using the most generic case, in which the genome-editing strategy does not incorporate specific features that facilitate identification of the desired modification. As a result, Steps 37-47 use the Surveyor nuclease to determine whether efficient modification has occurred in pooled genomic DNA. Sanger sequencing is used in Steps 51-54 to genotype individual clones.
However, it is preferable to design features into the genome-editing strategy that facilitate identification of clones with the desired genotype without relying on Sanger sequencing. In cases in which a simple deletion is desired, using two gRNAs spaced ~100 bp apart may slightly increase mutation efficiency 10 and will facilitate genotyping of individual clones. For HDR, the DNA donor could be designed to insert or remove a restriction endonuclease site (Box 1). If these features are incorporated into the genome-editing strategy, then they can be substituted for Steps 37-47 and 51-54. Controls. A negative control (omission of gRNA) should be included in the workflow. A useful positive control for newcomers to the protocol is to target the TAZ locus using the sequences outlined in Supplementary Data 2. TAZ, located on the X chromosome, is present in a single copy in XY iPSCs. Gel electrophoresis tanks, horizontal (Owl EasyCast B2) Gel electrophoresis power supply (Bio-Rad PowerPac300) Gel documentation system (UVP GelDoc-It) PCR thermocycler (Bio-Rad C1000 Touch) A gRNA is designed to introduce a double-strand break (DSB, red lines) close to the desired modification site (blue). The HDR donor oligo is designed to have homology arms that are at least 45-nt long on either side of the desired sequence modification (purple). Two additional sequence modifications are desirable if they can be achieved without impacting the ultimate experimental goal. First, introduce 'silent' sequence variants (magenta) that eliminate the gRNA recognition sequence after HDR. Second, introduce or remove a restriction enzyme site so that HDR genomes can be identified by restriction digestion of PCR products (green). Genotyping PCR primers are designed flanking the targeted region. These genotyping primers should not overlap the homology arms.
MaterIals

REAGENTS
proceDure establishment of a Dox-inducible ips/es line • tIMInG 33 d to obtain candidate lines 1| Grow low-passage iPSCs (between passages 10 and 40) to 70% confluence in a six-well plate. iPSCs should be grown in dedicated tissue culture incubators (37 °C, 5% CO 2 , humidified).  crItIcal step It is crucial that cell culture environments be free of mold, bacteria and mycoplasma.
2| Prepare a Matrigel-coated six-well dish (Box 2) and place it in the tissue culture incubator.
3| Lift cells as directed in Box 3.
 crItIcal step To achieve highly efficient transfection, the cells must be dissociated into single cells.
4|
Count the cells with a hemocytometer. Adjust the cell density with PBS to 1 million cells per ml. 11| Add 500 µl of mTeSR1 medium with 10 µM Y-27632 to the nucleofection cuvette and aspirate the nucleofected cells from the cuvette using the provided plastic pipette.
12|
Transfer the cells drop-wise into one well of the Matrigel-coated six-well dish from Step 2, and incubate the cells at 37 °C overnight.
13|
The next day (day 1 after nucleofection) change the medium to mTeSR1 and add puromyocin at a final concentration of 1 µg/ml. Thereafter, change the medium with puromycin daily. Nonresistant cells will die, peaking at day 4. When distinct colonies are visible to the naked eye (usually about day 7), proceed to the next step.
? trouBlesHootInG 14| Prepare a 10-cm Matrigel-coated dish (Box 2) and place it in the tissue culture incubator.
15| Lift the cells as described in 
25|
Calculate the copy number per genome using the following formula: 2 × 2^(Ct EIF2C1 -Ct Cas9 ).  crItIcal step When interpreting the data, keep in mind that in our experience this assay underestimated by about three fold the actual transgene copy number, determined by whole-genome sequencing and confirmed by targeted PCR amplification of each transgene. If digital droplet PCR is available, it may estimate transgene copy number slightly more accurately using the same qPCR probe assays (supplementary Fig. 3 ). markers (qRTPCR and immunostaining for Oct4, Nanog and Sox2) 20 . Confirm normal karyotype by performing G-banded karyotyping through a cytogenetics testing service. Using qRTPCR 21 and the hCas9 qPCR probe assay, confirm robust Cas9 upregulation by DOX (2 µg/ml). Confirm Cas9 excisability as detailed in Steps 55-62.
27|
Expand and freeze (Box 5) the best 2-3 lines for future use.
Genome editing using the stable ipsc-hcas9-pB cell line • tIMInG 5 d 28| Prepare one of the iPSC-hCas9-PB stable cell lines from
Step 27 for nucleofection, as described in Steps 1-8.
29|
To the cell suspension, add the following DNAs in a maximum volume of <20 µl:  crItIcal step We found that 4 µg of gRNA expression construct is the minimal amount required for high (70-80%) transfection efficiency and >20 µg of DNA will cause excessive cell death. Generally, 10 µg works best, but increasing or decreasing the amount can improve efficiency.  crItIcal step Addition of excision-only PB transposase plasmid is optional; for one-step genome editing with concurrent removal of the hCas9-PB transgene, add 2 µg of excision-only PB expression plasmid to the transfection mix. If further genome editing is planned, omit this step.
30|
Repeat Steps 10-12, adding Dox at a final concentration of 2 µg/ml to the cells in the six-well plate before overnight incubation.
31|
The next day, change the medium to mTeSR1 with Dox (2 µg/ml) but without Y-27632. Change the medium daily with mTeSR1 containing Dox (2 µg/ml). 
33|
On the fifth day after nucleofection, prepare three Matrigel-coated 10-cm dishes (Box 2).
34| Lift cells from
Step 32 (as described in Box 3). Adjust the cell density with DPBS to 100,000 cells/ml. 52| Submit the PCR product for Sanger sequencing with appropriate sample processing for crude PCR products.
53|
Analyze the Sanger sequencing chromatograms to detect desired sequence changes. Software such as PolyPeakParser 22 may help to deconvolute overlapping, out-of-phase chromatograms, which frequently result from indel mutation on one or both alleles. It may be necessary to clone PCR amplicons (e.g., using a TA Cloning Kit) and then sequence individual bacterial colonies to definitively determine the sequence of each individual allele. ? trouBlesHootInG 54| If piggyBac transposase was included in the transfection mix in Step 28, then also perform genotyping for the hCas9 transgene as described in Steps 20-22.
piggyBac transposon removal • tIMInG 20 d  crItIcal If multiple genome-editing steps are anticipated, it may be desirable to leave the piggyBac transposon in place, and then remove it at a final independent step.
55| Expand iPSC clones (from
Step 50) that have the desired genotype and contain the hCas9 transgene, as described in Box 4.
56|
On the day before transfection, prepare a Matrigel-coated 10-cm dish (Box 2).
57|
On the day of transfection, remove the solution from the Matrigel-coated 10-cm dish. Replace it with 6 ml of mTeSR1 medium with 10 µM Y-27632.
58| Prepare the iPSC clone from
Step 55 for nucleofection, following Steps 1-8.
59|
To the cell suspension, add 2 µg of excision-only piggyBac transposase plasmid.
60|
Repeat Steps 10 and 11. 
62|
The next day, change the medium to mTeSR1 without Y-27632 and change the medium daily.
63|
Once the clones are big enough to see with the naked eye (~12 d), pick 10 and expand (Box 4). The procedure in Box 4 will yield iPSC clones in a 24-well dish, to be used in Step 64, and matching genomic DNA samples, to be analyzed in Step 65. antIcIpateD results The first stage of this protocol is to integrate the piggyBac transposon containing the Dox-inducible Cas9 expression cassette into iPSCs, to yield iPSC-Cas9-PB. This step needs to be done only once to obtain a common parental line that is conducive to genome editing. Genome editing using iPSC-Cas9-PB cells is highly efficient. As shown in Figure 2 and supplementary Fig. 1 , we routinely obtain clones in which 19% have undergone HDR and 54% have undergone NHEJ. The Surveyor nuclease assay is a useful predictor of efficient genome modification: if a robust nuclease cleavage product is observed, then analysis of 48-96 clones will probably yield the desired genome-edited product. On the other hand, a weak or absent nuclease cleavage product (Fig. 6) suggests that the experiment should be halted and steps should be taken to troubleshoot the genomeediting efficiency (table 1) coMpetInG FInancIal Interests The authors declare competing financial interests: details are available in the online version of the paper.
64|
